UY28293A1 - Formulacion farmaceutica de la sal sodica del telmisartan - Google Patents

Formulacion farmaceutica de la sal sodica del telmisartan

Info

Publication number
UY28293A1
UY28293A1 UY28293A UY28293A UY28293A1 UY 28293 A1 UY28293 A1 UY 28293A1 UY 28293 A UY28293 A UY 28293A UY 28293 A UY28293 A UY 28293A UY 28293 A1 UY28293 A1 UY 28293A1
Authority
UY
Uruguay
Prior art keywords
telmisartan
sodium salt
pharmaceutical formulation
benzimidazol
methyl
Prior art date
Application number
UY28293A
Other languages
English (en)
Inventor
Anja Kohlrausch
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33305059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28293(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY28293A1 publication Critical patent/UY28293A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/39—Heterocyclic compounds having sulfur as a ring hetero atom having oxygen in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

El invento se refiere a una formulación medicamentosa de la sal sódica cristalina del 4^-((2-n-propil-4-metil-6-(1-metil-bencimidazol-2-il)-bencimidazol -1-ilmetil)- bifenil-2-casrboxílico (telmisartán), así como procedimientos para su preparación.
UY28293A 2003-04-30 2004-04-28 Formulacion farmaceutica de la sal sodica del telmisartan UY28293A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10319450A DE10319450A1 (de) 2003-04-30 2003-04-30 Pharmazeutische Formulierung des Telmisartan Natriumsalzes

Publications (1)

Publication Number Publication Date
UY28293A1 true UY28293A1 (es) 2004-11-30

Family

ID=33305059

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28293A UY28293A1 (es) 2003-04-30 2004-04-28 Formulacion farmaceutica de la sal sodica del telmisartan

Country Status (22)

Country Link
EP (1) EP1622612B9 (es)
JP (2) JP5156231B2 (es)
KR (1) KR20060008943A (es)
CN (1) CN100589802C (es)
AR (2) AR044142A1 (es)
AT (1) ATE388703T1 (es)
AU (1) AU2004233581B2 (es)
BR (1) BRPI0409809A (es)
CA (1) CA2524091C (es)
CL (1) CL2004000899A1 (es)
DE (2) DE10319450A1 (es)
DK (1) DK1622612T3 (es)
ES (1) ES2303634T4 (es)
IL (1) IL171465A (es)
MX (1) MXPA05011647A (es)
NZ (1) NZ543775A (es)
PE (1) PE20050464A1 (es)
RU (1) RU2372918C2 (es)
TW (1) TWI364278B (es)
UY (1) UY28293A1 (es)
WO (1) WO2004096215A1 (es)
ZA (1) ZA200507223B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
DE10319592A1 (de) * 2003-05-02 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Behandlung von diabetischer Retinopathie mit Angiotensin II-Rezeptorblockern
WO2006044754A2 (en) * 2004-10-18 2006-04-27 Dr. Reddy's Laboratories Ltd. Process for preparing telmisartan
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
CA2654890C (en) * 2006-06-16 2015-10-06 Lek Pharmaceuticals D.D. Pharmaceutical composition
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2009058950A2 (en) * 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
CZ2008740A3 (cs) 2008-11-24 2010-01-06 Zentiva, A.S. Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
JP2011136908A (ja) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法
CA2706292A1 (en) * 2010-05-28 2011-11-28 Pharmascience Inc. A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
KR102117282B1 (ko) * 2010-11-15 2020-06-01 베링거 인겔하임 인터내셔날 게엠베하 혈관보호성 및 심장보호성 항당뇨 치료요법
WO2013030725A1 (en) * 2011-08-26 2013-03-07 Wockhardt Limited Methods for treating cardiovascular disorders
CN102526037B (zh) * 2012-02-10 2014-08-27 重庆康刻尔制药有限公司 一种替米沙坦药物组合、片剂及其制备方法
EP2649996A1 (en) * 2012-04-11 2013-10-16 Laboratorios Del. Dr. Esteve, S.A. Crystalline forms of sartans like telmisartan with beta blockers
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
JP6428340B2 (ja) * 2014-05-23 2018-11-28 ニプロ株式会社 テルミサルタンを含む医薬組成物の造粒方法
JP5956034B1 (ja) * 2015-07-27 2016-07-20 エルメッド エーザイ株式会社 テルミサルタン含有医薬組成物
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
JP4107831B2 (ja) * 2000-11-21 2008-06-25 第一三共株式会社 医薬組成物
US20040242891A1 (en) * 2001-10-26 2004-12-02 Jonathan Campbell Production of keto acids
DE10153737A1 (de) * 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
ES2298351T5 (es) * 2002-01-16 2012-01-26 BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Método para producir un comprimido farmacéutico de dos capas que comprenden telmisartán e hidroclorotiazida.
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes

Also Published As

Publication number Publication date
TW200509914A (en) 2005-03-16
CA2524091A1 (en) 2004-11-11
PE20050464A1 (es) 2005-07-04
MXPA05011647A (es) 2005-12-15
AU2004233581B2 (en) 2010-04-22
NZ543775A (en) 2009-03-31
AR087210A2 (es) 2014-02-26
EP1622612B1 (de) 2008-03-12
KR20060008943A (ko) 2006-01-27
CN1780618A (zh) 2006-05-31
AR044142A1 (es) 2005-08-24
RU2372918C2 (ru) 2009-11-20
BRPI0409809A (pt) 2006-05-09
AU2004233581A1 (en) 2004-11-11
JP5156231B2 (ja) 2013-03-06
ES2303634T4 (es) 2009-04-01
TWI364278B (en) 2012-05-21
DE502004006500D1 (de) 2008-04-24
ATE388703T1 (de) 2008-03-15
CN100589802C (zh) 2010-02-17
JP5254268B2 (ja) 2013-08-07
JP2006524635A (ja) 2006-11-02
CA2524091C (en) 2012-02-21
EP1622612A1 (de) 2006-02-08
DE10319450A1 (de) 2004-11-18
ZA200507223B (en) 2006-05-31
EP1622612B9 (de) 2008-11-05
JP2010138207A (ja) 2010-06-24
WO2004096215A1 (de) 2004-11-11
ES2303634T3 (es) 2008-08-16
RU2005137031A (ru) 2007-06-10
CL2004000899A1 (es) 2005-03-04
IL171465A (en) 2010-06-30
DK1622612T3 (da) 2008-05-26

Similar Documents

Publication Publication Date Title
UY28293A1 (es) Formulacion farmaceutica de la sal sodica del telmisartan
CR11474A (es) Derivados de aminobenzamida como agentes utiles para el control de parasitos de animales.
CY1119261T1 (el) Παραγωγα θειαζολιου
DOP2012000011A (es) Formulacion farmaceutica
DOP2006000170A (es) Nuevos derivados de espirocromanona
SV2011004077A (es) Derivados aminobutiricos sustituidos como inhibidores de neprilisina
CO6470847A2 (es) Derivados amino-propiónicos sustituidos como inhibidores de neprilisina
HN2012001413A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
UY31350A1 (es) (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos
GT201200126A (es) Derivados de la cromenona con actividad anti-tumoral
CO6571900A2 (es) Composiciones famaceúticas del compuesto espiro-oxindol para adminsitración tópica y sus usos como agentes terapeúticos
CR20130530A (es) Derivados glucósidos y sus usos para el tratamiento de la diabetes
UY27520A1 (es) Sal sódica cristalina, procedimiento para su preparación y su uso para la preparación de un medicamento
MX2011013869A (es) Agentes antihelminticos y su uso.
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
AR077915A1 (es) Forma cristalina de pemirolast
CU20130004A7 (es) Agentes terapéuticos 976
MX2022010574A (es) Composicion farmaceutica que comprende compuesto derivado de bencimidazol.
MX2023006696A (es) Composiciones farmaceuticas que comprenden un agonista cannabinoide.
PA8845501A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes de curación de heridas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150525